Everand Logo

Welcome to Everand!

  • STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A FTC PBM Report, A Kroger Deal On Opioids, And More News
    A bipartisan group of lawmakers is calling on the FTC to release an interim staff report on pharmacy benefit managers
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Pharma Layoffs, Moderna Gambling On China, And More
    The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FDA Commish’s Parting Thoughts, A Warning On RSV Shots, And More
    Departing FDA leader Robert Califf defended the agency’s record and praised its progress on regulating food
    STAT1 min readAmerican Government
    STAT+: Leaving FDA, Califf Is Unapologetic — And Warns Of Staff Departures
    In an interview, outgoing FDA commissioner Robert Califf was wary of the Trump administration but unapologetic about controversial decision during his term.
    STAT1 min read
    STAT+: Johnson & Johnson Says Its Lung Cancer Drug Significantly Extended Survival
    Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer patients.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FDA Guidance On AI, Meds Releasing ‘Forever Chemicals,’ And More
    The FDA published its first draft guidance on the use of AI in the development of drugs and biological products
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Novo And GLP-1 Compounding, Paxlovid And Long Covid, And More
    Novo Nordisk filed another petition with the FDA seeking to block compounding pharmacies from making versions of one of its GLP-1 drugs
    STAT1 min read
    Opinion: The Surgeon General Is Right: America Has A Drinking Problem
    The alcohol industry relies on the myth of “responsible enjoyment” to downplay its products’ risks while spreading misinformation to stifle regulation.
    STAT2 min read
    People From India Remember Life Before The Polio Vaccine. They Don’t Want To Go Back
    Indian-Americans who remember life before the polio vaccine are worried about what RFK Jr. could do in the U.S.
    STAT1 min read
    STAT+: 3 Trends To Watch In Telehealth In 2025
    After multiple short-term extensions, telehealth providers are eager for Congress to lay out its long-term plans for the sector.
    STAT1 min read
    STAT+: Lawmakers Call For Curbs On UnitedHealth’s Growing Empire
    U.S. senators and other lawmakers argue the problems created by UnitedHealth's size and reach demand steps to restore public confidence in the health care system
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About The End Of A Lilly Drug Shortage, A Novo Obesity Trial Disappointment, And More
    Novo Nordisk’s next-generation obesity candidate led to substantial weight loss in a pivotal study but fell short of expectations
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Vertex Pain Drug, The Feds Suing CVS Over Opioids, And More
    Vertex's closely watched drug, suzetrigine, reduced sciatica pain compared to baseline but did not outperform a placebo
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Merck Deal For An Obesity Pill, A Departing FDA Official, And More
    Merck signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's oral obesity drug
    STAT1 min readAmerican Government
    Opinion: STAT+: Pharmacy Benefits Managers Should Be Worried
    Former FTC policy director David Balto says PBMs should be very worried about the new Trump administration and pending congressional action.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Congress Reining In PBMs, Sanofi Suing HHS, And More
    After two years of haggling, Congress has nearly reached a deal to rein in pharmacy benefit managers
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Novo Holdings Proceeding With Catalent Deal, Sanofi Threatened With Sanctions, And More
    Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge the deal
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Editas Layoffs, House Republicans Probing CVS, And More
    Editas plans to lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell disease
    STAT1 min read
    STAT+: Ionis Blazed Trails In Genetic Medicine. On The Cusp Of A Major Approval, Can It Also Be A Commercial Success?
    Ionis is expecting a FDA decision by Dec. 19 on approval of a drug designed to improve the body’s ability to break down fats
    STAT1 min read
    STAT+: For A Leukemia That Keeps Returning, AbbVie Drug May Offer Chance For A Deep Remission
    Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to kick."
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Unsupported Drug Price Hikes, An Annual HIV Prevention Shot, And More
    Gilead plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with a single shot every year
    STAT1 min read
    Opinion: In A Threat To Patient Trust, Texas Hospitals Must Ask ‘Are You A U.S. Citizen?’
    Akshara Ramasamy will soon begin medical school in Texas — but the state’s new requirement to ask hospital patients about immigration status worries her.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Bill To Force Insurers To Sell Pharmacies, Lilly Testing GLP-1 Meds For Addiction, And More
    A bipartisan group of senators are filing a bill that would force health insurers or PBMs to divest their pharmacy businesses
    STAT1 min read
    STAT+: Do GLP-1s Work For Parkinson’s? A Health Tech Startup Pitches Pharma On Quick Answers
    Why digital measurements startup Koneksa Health thinks it can help pharma measure if their drugs are effective in people with Parkinson's disease.
    STAT1 min read
    STAT+: With Promising Early Data In Triple Negative Breast Cancer, A New Bispecific Heats Up
    New data suggests researchers may have found one of their most promising candidates yet for the next generation in immunotherapy drugs — bispecific antibodies targeting two key proteins in cancer, PD1 or PD-L1 and VEGF.A small early trial on one such
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Pharma Not Lobbying Against RFK Jr., A Supreme Court 340B Appeal, And More
    The pharmaceutical industry is not lobbying senators to stop the confirmation of long-time critic Robert F. Kennedy Jr.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Biosecure Act Setback, A Judge Ordering Release Of Covid Vaccine Data, And More
    The BIOSECURE Act, which would restrict drugmakers from using key Chinese contract manufacturers, was left out of a defense budget bill 
    STAT1 min read
    STAT+: Inside A Nobel-winning Marriage: They See Each Other As Scientific Equals, Even If The Prize Committee Doesn’t
    Ambros and Lee's collaboration helped spawn a new field of biology while proving breakthrough science can come out of a family-friendly lab
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Cracks In The MAHA Alliance, Pharmacies Suing GoodRx And PBMs, And More
    The diverse alliance that makes up the MAHA movement is showing some cracks over Trump's picks to lead health-related agencies
    STAT1 min read
    STAT+: Trump’s Win Puts Future Oversight Of Lab-made Tests In Jeopardy
    WASHINGTON — The Food and Drug Administration has always believed it has the power to regulate tests made in labs. But it was only under President Biden that it began actively exercising that authority, releasing a policy in April telling labs they h

    More Publications

    …Or Discover Something New
    Browse Articles